We conducted a prospective open-label study with 100 outpatients who had sought psychiatric consult in private clinical practice for anxiety/sleep in subthreshold/ full blown DSM-IV Anxiety Spectrum Disorders. Clinicians, prescribed for 4 weeks a dietary supplement based on a formulation containing α-casozepine peptide 300 mg/day. The comparison of all rating scales mean scores reported at T0 versus T1 showed a statistically significant decrease (p<0.001). In Clinical Global Impression scale, the 54% of the sample was found to be much improved, 27% minimally improved and 19% showed no change. The 64% of the sample reported an anxiolytic effect, and among the 64 patients with sleep disorders, the 51.5% reported a pro-hypnotic effect. Considering patients in monotherapy with the dietary supplement, an anxiolytic effect was observed in 69.7% while a prohypnotic effect was observed in the 62.5% of the sample. No side-effects were reported during the treatment with no drop-out.
Giuseppe Ceraudo, Sonia Cortopassi, Lavinia Rossi, Bernardo Dell’Osso and Liliana Dell’Osso
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2018 All rights reserved. iMedPub Last revised : February 18, 2018